These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28723887)

  • 1. In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.
    Ricci F; Catozzi C; Ravanetti F; Murgia X; D'Aló F; Macchidani N; Sgarbi E; Di Lallo V; Saccani F; Pertile M; Cacchioli A; Catinella S; Villetti G; Civelli M; Amadei F; Stellari FF; Pioselli B; Salomone F
    Pediatr Res; 2017 Dec; 82(6):1056-1063. PubMed ID: 28723887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW; Oh M; Sin JB
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
    Ricci F; Murgia X; Razzetti R; Pelizzi N; Salomone F
    Pediatr Res; 2017 Feb; 81(2):369-375. PubMed ID: 27973472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: in vitro and in vivo evaluation of a neonate-focused nebulized surfactant delivery strategy.
    Bianco F; Ricci F; Catozzi C; Murgia X; Schlun M; Bucholski A; Hetzer U; Bonelli S; Lombardini M; Pasini E; Nutini M; Pertile M; Minocchieri S; Simonato M; Rosa B; Pieraccini G; Moneti G; Lorenzini L; Catinella S; Villetti G; Civelli M; Pioselli B; Cogo P; Carnielli V; Dani C; Salomone F
    Respir Res; 2019 Jul; 20(1):134. PubMed ID: 31266508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
    Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
    Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
    Manley BJ; Kamlin COF; Donath S; Huang L; Birch P; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Wilson R; Davis PG; McKinlay CJD
    Trials; 2023 May; 24(1):320. PubMed ID: 37161488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
    Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
    PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
    Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
    JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome].
    Xu H; Xu P
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):174-179. PubMed ID: 33729136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
    Rey-Santano C; Mielgo VE; Gomez-Solaetxe MA; Bianco F; Salomone F; Loureiro B
    Crit Care Med; 2020 Jun; 48(6):e523-e531. PubMed ID: 32301841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.
    Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A
    Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study.
    Yeh TF; Lin HC; Chang CH; Wu TS; Su BH; Li TC; Pyati S; Tsai CH
    Pediatrics; 2008 May; 121(5):e1310-8. PubMed ID: 18426851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.